Pharmaceuticals, Biotechnology and Life Sciences
— Filgotinib 200 mg Demonstrated Greater Efficacy Compared with Placebo in the Induction and Maintenance of Remission in the SELECTION…
— Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone — —…
Galapagos has discovered GLPG3312, a first generation compound against a novel and undisclosed inflammation target class, and it started Phase 1 trial.
Servier and Galapagos NV have started a global Phase 2 trial with S201086/GLPG1972 in knee osteoarthritis patients, titled Roccella, in…
Galapagos NV announced on Tuesday three new Phase 2 Proof-of-Concept studies investigating filgotinib in Sjögren`s syndrome, ankylosing spondylitis, and psoriatic arthritis.
Galapagos NV has reached a milestone in a Phase 1 study for cystic fibrosis, it is conducting with its partner AbbVie, …
Galapagos NV has started two new Phase 2 studies of filgotinib in small bowel Crohn`s disease and in fistulizing Crohn`s disease, both led by filgotinib collaboration partner Gilead Sciences.
Galapagos has started dosing the first healthy volunteer with a combination of novel corrector GLPG2222 and novel potentiator GLPG2451 for cystic fibrosis in a Phase 1 study.
Galapagos has appointed Dr. Walid Abi-Saab as a Chief Medical Officer (CMO), who came from Shire Pharmaceuticals, beginning on March 1, 2017.
Galapagos has reported topline results from its Saphira 1 Phase 2 study in cystic fibrosis patients with potentiator GLPG1837.